A retrospective study assessing the prostate-specific antigen (PSA) outcomes among patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide
Latest Information Update: 23 Mar 2020
At a glance
- Drugs Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
Most Recent Events
- 23 Mar 2020 New trial record
- 15 Feb 2020 Results presented at the 2020 Genitourinary Cancers Symposium